目的：比较胃溃疡与溃疡型胃癌的发病特点。方法：对69例胃溃疡与32例胃癌进行回顾性分析，比较二者好发年龄、胃镜下变病部位和大小的差异。结果：63.7%胃溃疡多发生于50岁以下患者，81.3%胃癌发生于50岁以上患者（Ｐ＜0.01）。贲门部的胃癌是胃溃疡的5倍（Ｐ＜0.01）；胃角部的胃溃疡是胃癌的9倍（Ｐ＜0.01）；溃疡型胃癌与胃溃疡都易发生在胃窦，且检出率相似。82.6%胃溃疡直径＜3 cm，78.1%胃癌直径≥3 cm（Ｐ＜0.01）。结论：胃溃疡与溃疡型胃癌的好发年龄、生长部位和大小几乎各不相同，这些发病特点对溃疡型胃癌的早期诊断有一定指导意义。
目的 探究静脉利多卡因联合异丙酚在无痛胃镜麻醉应用中的可行性、安全性和有效性。 方法 纳入2012年4月－5月行无痛胃镜检查的患者102例，随机分为两组：利多卡因组（L组）和生理盐水组（S组）。L组于麻醉诱导前缓慢静注2%利多卡因2 mg/kg，S组给予相同容量的生理盐水。比较两组间的异丙酚诱导剂量、追加剂量和总量，以及检查中呛咳反应、体动的发生率，麻醉时间，不良事件和不良反应发生率，麻醉医生和患者满意度是否有差异。 结果 L组较S组异丙酚诱导剂量减少约0.17 mg/kg，差异有统计学意义（P=0.03）；余指标差异均无统计学意义。 结论 将静脉利多卡因用于无痛胃镜麻醉，虽能减少异丙酚诱导剂量，但减少程度并不明显；不能改善诱导前后血流动力学的剧烈波动，也未能缩短总的麻醉时间；在抑制术中呛咳反应、体动方面也未见明显优势。无论是从安全性还是经济学方面考虑，我们都不推荐将静脉利多卡因联合异丙酚麻醉的方案用于无痛胃镜检查。
目的:讨论胃镜检查中更加舒适的一种镇静镇痛方法。方法:芬太尼-异丙酚为Ⅰ组,咪唑安定-异丙酚组为Ⅱ组。观察记录各组术中的反应、胃镜操作时间、麻醉药物起效时间、苏醒时间和清醒时间,检查前中后BP、HR和SpO2的变化,及术后问卷调查。结果:Ⅰ组药物的起效快,受检者苏醒及清醒时间短,术中不适反应少,与Ⅱ组比较有统计学意义(Plt;0.01)。结论:镇静无痛苦胃镜检查中芬太尼-异丙酚联合用药更舒适。
摘要:目的: 研究分析特殊饮食结构和生活习惯人群发生上消化道疾病的病种及发生率。 方法 :对1998年11月至2008年11月我院经胃镜检查的3661例患者进行统计,并参考饮食结构和生活习惯进行分析。 结果 :汉族调查2343例,彝族调查1318例:汉族患病率胃溃疡1626%、十二指肠溃疡858%、复合性溃疡098%、糜烂出血性胃炎1434%、胃癌、食道癌089%;彝族患病率胃溃疡2527%、十二指肠溃疡1282%、复合性溃疡25%、糜烂出血性胃炎1988%、胃癌、食道癌152%。 结论 :少数民族地区特殊饮食人群上消化道疾病发病率及胃、十二指肠溃疡的发生率和癌变比率明显增高。Abstract: Objective: To study the structure of the special diet and the lifestyle of people who occurred the upper digestive tract diseases and disease incidence. Methods : From 199811 t0 200811,3661 cases in our hospital carryed out statistics and analysis with reference to diet and lifestyle. Results : Han people with 2343 cases, Yi people with 1318 cases, in Han people, the rate of ulcer was 1626%,858% of duodenal ulcer,098% of compound ulcer,1434% of erosive hemorrhage gastritis,089% of stomach and esophagus; in Yi people,2527% of gastric ulcer,1282% of duodenal ulcer,25% of compound ulcer,1988% of erosive gastritis hemorrhage,152% of stomach and esophageal cancer. Conclusion : The upper digestive tract diseases, the incidence of stomach, duodenal ulcer and cancer incidence rate increased significantly in special diet groups in ethnic minority areas.
Objective To analyze the clinicopathologic characteristics of remnant gastric cancer （RGC）. Methods The clinical data of 114 patients with RGC treated in The Second Affiliated Hospital of Northern Sichuan MedicalCollege and The General Hospital of Chinese People’s Liberation Army from March 2000 to May 2008 were reviewed and analyzed retrospectively. The clinicopathologic characteristics between the patients with primary benign diseases and those with malignant diseases were evaluated. Results A total of 114 cases，the age was （62.6±11.3） years，and the males versus females was 4.7∶1.0. Most patients （76.2%，64/84） were diagnosed at advanced stages （consistent with pT），and the proportion of pT1 stage cases was only 23.8% （20/84），tumor invasion pT4 was 60.7% （51/84）. It was more common that tumor directly invaded adjacent organs or structures （27.4%，23/84），lymph nodes positive （42.9%，36/84），and distant metastasis （27.2%，31/114）. The location of distant metastasis was usually confined in the abdominal cavity （93.5%，29/31），and the peritoneum disseminated was the most commonly structures （67.7%，21/31）. Histologically，the incidence of poorly differentiated adenocarcinoma （76.7%，79/103） was the mostly histologic grade as well as the diffuse type （78.6%，81/103） was the mostly Laurén classification. Between the patients with primary benign diseases and those with initial malignant disease，the initial gastrectomy or the methods of reconstruction had significantly differences （both P=0.000）. The median time from initial resection to development of RGC was 30.0 years in the patients with original benign disease，contrary to 3.3 years in those with previous malignant disease （P=0.000）. Both primary diseases （benign or malignant） and the age at initial gastrectomy were the major influencing factors for the time of RGC developed （P＜0.05）. For pathohistology characters，except signet-ring cell carcinoma （P=0.045）， pT4b （P=0.049），pN stage （P=0.025），and Borrmann classification （P=0.005），there were no significant differences between the patients with previous benign diseases and those with original malignant disease，as well as the resectability rate，curative resection （R0） rate，and overall survival rate （P＞0.05）. Conclusions It is almost unaffected by originalbenign diseases or malignant diseases for clinicopathologic characteristics including the treatment option and prognostic factors.It is necessary and feasibility to form a pattern of endoscopic follow-up for RGC.
ObjectiveTo explore the clinical effect of lidocaine mucilage diluent and simethicone emulsion in gastroscopy examination, in order to provide effective drugs for gastroscopy. MethodsWe selected 201 outpatients and the inpatients who underwent gastroscopic examination between August and October 2014 as the research subjects. Based on the kind of drug, the patients were randomly divided into research group (n=100) and control group (n=101). Patients in the research group accepted lidocaine mucilage diluent, while those in the control group received simethicone emulsion. Then we observed and compared the definition of gastroscopy, adverse drug reactions, examination time and drug price between the two groups. ResultsThe frequencies of high, medium, and low definition of gastroscopy were respectively 63.00%, 34.00% and 3.00% among the patients in the research group, and 69.31%, 26.73% and 3.96% among patients in the control group; there was no significant differences between the two groups (Z=-0.854, P=0.393). The adverse reaction rates, testing time, and drug prices for the two groups were 0.99% vs.1.00% (P>0.05), (6.5±2.1) minutes vs.(6.6±2.0) minutes (t=0.458, P>0.05), and RMB (9.0±1.2) yuan vs.(42.8±2.8) yuan (t=227.644, P<0.05), respectively. ConclusionLidocaine mucilage diluent and simethicone emulsion both have good effect for gastroscopic examination, which can raise the gastroscopic definition, promote endoscopic operation and observation by doctors, shorten examination time, and reduce adverse drug reactions. Both are of great value in clinical application, and lidocaine hydrochloride mucilage diluent is cheaper, which can be widely used and promoted clinically.
ObjectivesTo systematically review the efficacy of dyclonine and lidocaine for preparation before gastroscopy.MethodsPubMed, CNKI, CBM, VIP and WanFang Data databases were electronically searched to collect randomized controlled trials (RCTs) of dyclonine vs. lidocaine for preparation before gastroscopy from inception to December 31st, 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed by using RevMan 5.3 software.ResultsA total of 11 RCTs were included. The results of meta-analysis showed that: dyclonine could improve anesthetic effect (RR=1.38, 95%CI 1.31 to 1.47, P<0.000 01), and was more capable to remove bubble (RR=1.40, 95%CI 1.28 to 1.52,P<0.000 01), and had superior textures (RR=1.43, 95%CI 1.18 to 1.74,P=0.000 3).ConclusionsOral dyclonine can improve the visual definition of gastric mucosa and anesthetic effect, and has superior textures. Thus, dyclonine can be regarded as a recommended option prior to gastroscopy. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.